Jasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Acquired by Integral Health Asset Management LLC

Integral Health Asset Management LLC lifted its holdings in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 85.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 650,000 shares of the company’s stock after acquiring an additional 300,000 shares during the period. Jasper Therapeutics accounts for approximately 1.2% of Integral Health Asset Management LLC’s investment portfolio, making the stock its 29th biggest holding. Integral Health Asset Management LLC’s holdings in Jasper Therapeutics were worth $13,897,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Wells Fargo & Company MN raised its position in shares of Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock worth $159,000 after acquiring an additional 3,828 shares in the last quarter. EntryPoint Capital LLC acquired a new position in Jasper Therapeutics during the fourth quarter worth approximately $223,000. Jane Street Group LLC purchased a new stake in Jasper Therapeutics in the third quarter valued at approximately $251,000. Rhumbline Advisers lifted its stake in Jasper Therapeutics by 12.6% in the fourth quarter. Rhumbline Advisers now owns 14,761 shares of the company’s stock valued at $316,000 after buying an additional 1,652 shares during the last quarter. Finally, Barclays PLC grew its position in shares of Jasper Therapeutics by 320.7% during the third quarter. Barclays PLC now owns 16,146 shares of the company’s stock worth $304,000 after acquiring an additional 12,308 shares during the last quarter. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Price Performance

Jasper Therapeutics stock opened at $4.52 on Monday. Jasper Therapeutics, Inc. has a 1-year low of $3.13 and a 1-year high of $26.84. The company has a market cap of $67.90 million, a PE ratio of -0.95 and a beta of 2.74. The stock’s 50 day moving average price is $4.66 and its 200 day moving average price is $11.43.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($1.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.35). On average, equities research analysts anticipate that Jasper Therapeutics, Inc. will post -4.47 EPS for the current fiscal year.

Analysts Set New Price Targets

JSPR has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. UBS Group initiated coverage on Jasper Therapeutics in a research note on Thursday, February 13th. They issued a “buy” rating and a $38.00 target price on the stock. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $62.50.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.